Latest available resultsQuarter ended June 28, 202610-Q · August 4, 2026
Filed with the SECPFIZER INC
PFEPharma & biotech
Next reportNovember 2, 2026Analyst forecast 0.765 $/share
Revenue
$15.03B
▲ +2.6% vs prior year% YoY
Net income
−$248.00M
▼ -108.5% vs prior year% YoY
EPS
-0.04$
▼ -107.8% vs prior year% YoY
Net margin
-1.6%
▼ -21.5 percentage points vs prior year pp YoY
Revenue▲ +2.6 %
Margins (% of revenue)GrossOperating N/ANet
Net income▼ -108.5 %
EPS▼ -107.8 %
View financial tableQuarter ended June 28, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $15.03B | |
| Gross profit | $10.94B | 72.8 % |
| Operating income | — | never filed |
| Net income | −$248.00M | -1.6 % |
| R&D | — | never filed |
| EPS (diluted) | -0.04 $ | |
| Balance sheet | ||
| Assets | $201.13B | |
| Liabilities | $115.64B | |
| Equity | $85.49B | |
| Cash | $976.00M | |
| Capital | ||
| Shares outstanding | 5.70B | as of 2026-07-29 |
| Public float | — | |